This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents. Top assignees: F. Hoffmann-La Roche Ag, Hoffmann-La Roche Inc.. Active years: 2016-2017.
Company Filing History:
Years Active: 2016-2017
Title: Patrick Iaiza: Innovator in Carcinogenicity Testing
Introduction
Patrick Iaiza is a notable inventor based in Saint Louis, France. He has made significant contributions to the field of substance testing, particularly in identifying potential carcinogenicity. With a total of 2 patents, his work has the potential to impact public health and safety.
Latest Patents
One of Patrick's latest patents is a "Process and apparatus for testing substances for potential carcinogenicity." This innovative apparatus includes a plate support for micro-well plates, a movable pipetting unit with multiple pipettes, and containers with liquid culture medium. It also features a dish support for placing dishes, spinners for spinning the dishes, suction cups for sealing the dishes, and belts for transporting the closed dishes to intermediate storage.
Another significant patent is the "Hanging droplet plate," which consists of multiple droplet compartments designed to receive liquid droplets. Each compartment is equipped with a microfluidic wetting barrier that prevents the droplet from spreading beyond its designated area. This design enhances the precision of liquid handling in various applications.
Career Highlights
Throughout his career, Patrick has worked with prominent companies such as Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has contributed to his expertise in the field of substance testing and innovation.
Collaborations
Patrick has collaborated with notable colleagues, including Thomas Zumstein and Tom Kissling. These partnerships have likely enriched his work and expanded the impact of his inventions.
Conclusion
Patrick Iaiza is a distinguished inventor whose work in carcinogenicity testing is paving the way for advancements in public health. His innovative patents reflect his commitment to improving safety and efficacy in substance testing.